Skip to main content
Home

Language & Country Selector for Desktop

language-selector-globe Egypt | en

Choose Location

  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Mexico | es
  • United States | en
  • Venezuela | es
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Singapore | en
  • Taiwan | zh
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • Italy | it
  • Latvia | lv
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Egypt | en
  • Israel | he
  • South Africa | en
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe Egypt

Choose Location

Americas Asia Pacific Europe International Middle East & Africa
  • Argentina | es
  • Australia | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Israel | he
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Latvia | lv
  • Lithuania | lt
  • Mainland China | zh
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
  • Venezuela | es
    • About 
      • Novartis in Egypt 
      • Strategy 
      • Diversity and Inclusion 
      • People and Culture 
      • Innovative Medicines 
      • Products 
      • Country Leadership Team 
        • Sherif Amin 
      A girl with a flower About
    • Patients and Caregivers 
      • Novartis Commitment to Patients and Caregivers 
      • Diseases 
      • Products 
      • Adverse Event Reporting 
      • Patient Partner Panel 
      A couple holding hands Patients and Caregivers
    • Healthcare Professionals 
      • Products 
      • Novartis Pipeline 
      • Adverse Event Reporting 
      • Novartis Clinical Trials 
      • Information for Physicians 
      Healthcare Professional Healthcare Professionals
    • ESG 
      • Ethical Behavior 
        • Code of Ethics 
        • SpeakUp 
      • Ethics, Risk and Compliance 
      • Access 
      • Environmental Sustainability 
      • Global Health 
      ESG ESG
    • News 
      • News Archive 
      • Media Releases 
      • Featured News 
      News News
    • Careers 
      • Career Search 
      • Meet the teams 
      • Personal Growth 
      • Early Talent 
      • How We Work 
      • Well-being 
      • Diversity and Inclusion 
      • Awards and Recognition 
      Careers Careers
    • Coronavirus 
      covid 10 grey image_0 COVID-19 Information Center
    • Contacts 
    Homepage Novartis in Egypt Home
Header
Homepage Novartis in Egypt

Novartis Egypt

At Novartis, we are reimagining medicine

Previous Next
Novartis in Egypt

Novartis in Egypt

Novartis was created in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its predecessor companies trace roots back more than 250 years, with a rich history of developing innovative products.

Learn More
Commitment to patients

The Novartis Commitment to Patients and Caregivers

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives.

Learn More
A girl with a flower

About Novartis

We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.

A couple holding hands

Patients and Caregivers

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives.

Healthcare Professional

Healthcare Professionals

Novartis works closely with healthcare professionals around the work to support their treatment of patients and collaborate on unmet needs.

Four colleagues sitting around a table at the office

People and Culture

Novartis is building an Inspired, Curious and Unbossed culture.

Careers

Careers

769 million lives touched by our products. Join us.

To report an adverse event or any drug related issues concerning Novartis medicinal products; please contact Novartis Patient Safety: Tel: +202 22861000 - Press 3 for reporting an adverse event. Fax: 002 02 26031702. E-mail: [email protected]

للإبلاغ عن أثر جانبى أو أي مشكلة دوائية متعلقة بمنتجات نوفارتس الطبية او الاجهزة ؛ يرجى الاتصال بقسم اليقظة الدوائية في شركة نوفارتس
[email protected] البريد الإلكترونى
 +202 22861000 : الهاتف
ثم اضغط 3 للإبلاغ عن أثر جانبي او الخط الأرضى 20224524036+

 +2 02 26031702 : الفاكس

Novartis Egypt

Navigate Novartis
  • Patients & Caregivers
  • Healthcare Professionals
  • ESG
  • News
  • Careers
Media Center
  • News Archive
Our Portfolio
  • Novartis Clinical Pipeline
  • Novartis Product Portfolio
Other Novartis websites
  • Global site
Footer Bottom
© 2023 Novartis AG
  • Privacy Policy
  • Terms of Use
  • Cookie Settings
  • Site Map
  • Web Accessibility
Novartis Site Directory
This site is intended for an audience in Egypt.